GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Elicera Therapeutics AB (OSTO:ELIC) » Definitions » Accounts Receivable

Elicera Therapeutics AB (OSTO:ELIC) Accounts Receivable : kr0.00 Mil (As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Elicera Therapeutics AB Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Elicera Therapeutics AB's accounts receivables for the quarter that ended in Jun. 2024 was kr0.00 Mil.

Accounts receivable can be measured by Days Sales Outstanding.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Elicera Therapeutics AB's Net-Net Working Capital per share for the quarter that ended in Jun. 2024 was kr0.71.


Elicera Therapeutics AB Accounts Receivable Historical Data

The historical data trend for Elicera Therapeutics AB's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elicera Therapeutics AB Accounts Receivable Chart

Elicera Therapeutics AB Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Accounts Receivable
- - - - -

Elicera Therapeutics AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Accounts Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Elicera Therapeutics AB Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.


Elicera Therapeutics AB Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Elicera Therapeutics AB's Days Sales Outstanding for the quarter that ended in Jun. 2024 is calculated as:

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Elicera Therapeutics AB's accounts receivable are only considered to be worth 75% of book value:

Elicera Therapeutics AB's Net-Net Working Capital Per Share for the quarter that ended in Jun. 2024 is calculated as:

Net-Net Working Capital Per Share
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(32.865+0.75 * 0+0.5 * 0-7.972
-0-0)/35.0933
=0.71

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.


Elicera Therapeutics AB Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Elicera Therapeutics AB's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Elicera Therapeutics AB Business Description

Traded in Other Exchanges
N/A
Address
Massans gata 10, World Trade Center Goteborg, 7th Floor, Goteborg, SWE, SE-412 51
Elicera Therapeutics AB is a Sweden-based clinical-stage immuno-oncology company developing cell and gene therapies for immune-based cancer treatments. The company's product portfolio consists of four drug candidates, two in the field of oncolytic viruses (ELC-100 and ELC-201) and two in the field of CAR T-cell treatments (ELC-301 and ELC-401), in addition to a universal CAR T-cell technology platform, iTANK (ELC-001), compatible with any CAR T-cell therapy for a multi-targeted attack on solid tumors.

Elicera Therapeutics AB Headlines

No Headlines